- Quellis Buyout: Catabasis acquired Quellis Biosciences in January 2021 to secure its preclinical hereditary angioedema (HAE) asset, QLS-215.
- New Name: The company officially renamed itself Astria Therapeutics in September 2021.
- New Ticker: It changed its Nasdaq stock ticker from CATB to ATXS.
- Astria Therapeutics was aquired by BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) for about $700 million on January 23, 2026.
No comments:
Post a Comment